A drug that mimics the activity of thyroid hormone significantly increases the amount of energy burned by fat tissue and promotes weight loss, an animal study of metabolism finds. The results were presented Sunday at The Endocrine Society’s 95th Annual Meeting in San Francisco.
Short-term use of antidepressants, combined with stress and a high-fat diet, is associated with long-term increases in body weight, a new animal study finds. The results will be presented Saturday at The Endocrine Society’s 95th Annual Meeting in San Francisco.
A type of drug normally used to treat heart failure and high blood pressure helped prevent weight gain and other complications related to a high-fat diet in an animal study. The results will be presented Saturday at The Endocrine Society’s 95th Annual Meeting in San Francisco.
A new osteoporosis drug hinders the growth of estrogen-sensitive cancer that has become resistant to treatment with tamoxifen, a study in mice shows.
Researchers at Johns Hopkins report that hospitalized patients do not receive more than one in 10 doses of doctor-ordered blood thinners prescribed to prevent potentially lethal or disabling blood clots, a decision they say may be fueled by misguided concern by patients and their caregivers.
Multiple drug classes commonly prescribed for common medical conditions are capable of influencing the onset and progression of Alzheimer’s disease.
Most teens have unsupervised access to their prescription drugs at home, including drugs with potential for abuse, finds a new study in the Journal of Adolescent Health.
A collaboration of scientists at Sanford-Burnham and the University of California, Santa Barbara, finds that rod-shaped particles, rather than spherical particles, appear more effective at adhering to cells where they’re needed.
Mice suffering from age-related heart disease saw a significant improvement in cardiac function after treatment with the FDA-approved drug rapamycin for just three months. Research at the Buck Institute shows how rapamycin impacts mammalian tissues, providing functional insights and possible benefits for a drug that can extend lifespan in mice as much as 14 percent. Researchers at the Mayo clinic are now recruiting seniors with cardiac artery disease for a clinical trial involving the drug.
Researchers at Whitehead Institute have identified a key target protein of glucocorticoids, the drugs that are used to increase red blood cell production in patients with certain types of anemia, including those resulting from trauma, sepsis, malaria, kidney dialysis, and chemotherapy. The discovery could spur development of drugs capable of increasing this protein’s production and thus increased numbers of red blood cells without causing the severe side effects associated with glucocorticoids.
A re-analysis of the data from a pivotal study of rosiglitazone found no increased risk of cardiovascular events associated with the controversial diabetes drug, according to researchers at the Duke Clinical Research Institute (DCRI).
A team of researchers has made a significant discovery which may have a dramatic impact on children stricken with Tay-Sachs disease, a degenerative and fatal neurological condition that often strikes in the early months of life. Available drugs may dramatically ease a child’s suffering, say scientists.
When injected into mice immediately following a traumatic event, a new drug prevents the animals from developing memory problems and increased anxiety that are indicative of post-traumatic stress disorder (PTSD). Howard Hughes Medical Institute scientists utilized mouse studies to suggest that a receptor called Oprl1 is altered in mice with PTSD-like symptoms. They then worked with a group at the Scripps Research Institute who had previously developed the Oprl1-targeted drug to examine its effects on fear memory modulation.
A newfound genetic marker promises to better predict warfarin dose in African-Americans, according to a study published online today in The Lancet.
In the first GWAS to focus on warfarin dose requirement in African-Americans, researchers have identified a common genetic variation that can help physicians estimate the correct dose of the widely used blood-thinning drug warfarin.
Eighty-three percent of cancer doctors report that they’ve faced oncology drug shortages, and of those, nearly all say that their patients’ treatment has been impacted, according to a study from researchers at the Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania that will be presented today at the 2013 annual meeting of the American Society of Clinical Oncology (Abstract #CRA6510). The results showed that shortages – which have hit especially hard among drugs to treat pediatric, gastrointestinal and blood cancers – have left physicians surveyed unable to prescribe standard chemotherapies for a range of cancers.
Adding bevacizumab (Avastin) to standard chemotherapy and radiation treatment does not improve survival for patients newly diagnosed with glioblastoma, a very aggressive form of brain cancer, researchers have found. The results of the large, multicenter study are being presented today at the American Society of Clinical Oncology (ASCO) annual meeting.
A Radiation Therapy Oncology Group trial found that adding bevacizumab to initial treatment for glioblastoma did not improve patient overall survival or progression-free survival,. Results were reported June 2 at the plenary session of the American Society of Clinical Oncology 2013 Annual Meeting.
Gene panel may help personalize therapy for aggressive brain tumors.
Many glioblastoma patients treated with bevacizumab (Avastin®) have significant deterioration in neurocognitive function, symptoms and quality of life.
On Wednesday, 5/29/13, the Wall Street Journal published an article titled “Africa’s Malaria Battle: Fake Drug Pipeline Undercuts Progress.” The piece outlines a counterfeit pharmaceutical problem that is top of mind at Saint Mary’s College where chemistry researchers have developed Paper Analytical Devices (PADs) that can screen whether an antimalarial drug is real.
Charles H. Hennekens, M.D., Dr.P.H. and colleagues from around the world, under the direction of the Clinical Trial Service and Epidemiology Studies Unit at the University of Oxford, conducted a world-wide meta-analyses using individual participant data from 280 trials of NSAIDs vs. placebo and 474 trials of NSAID vs. another NSAID, which involved a total of 353,809 participants and a total of 233,798 person-years. These results address risks and benefits of drugs used for relief of inflammatory arthritis including cardiovascular disease and other relevant outcomes such as gastrointestinal effects.
New guidelines to ensure the safe and effective use of blood thinners have been developed and endorsed by the Anticoagulation Forum.
A drug commonly used to treat depression and anxiety may improve a stress-related heart condition in people with stable coronary heart disease, according to researchers at Duke Medicine.
Among patients with stable coronary heart disease and mental stress-induced myocardial ischemia (MSIMI), 6 weeks of treatment with the antidepressant escitalopram, compared with placebo, resulted in a lower rate of MSIMI, according to a study in the May 22/29 issue of JAMA.
A novel approach to obstructing the runaway inflammatory response implicated in some types of asthma has shown promise in a Phase IIa clinical trial, according to U. S. researchers.
A new study of both computer-created and natural proteins suggests that the number of unique pockets – sites where small molecule pharmaceutical compounds can bind to proteins – is surprisingly small, meaning drug side effects may be impossible to avoid.
Honokiol is a powerful polyphenol compound extracted from Magnolia officinalis bark. Extensive pre-clinical research shows that honokiol (pronounced ha-no-kee-ohl) supports cellular health and provides gentle relaxation, as well as being a potent antioxidant. In addition, a study published in the European Journal of Pharmacology has found that the botanical extract protects muscles from the normal inflammation caused by intense exercise. This study broadens honokiol’s acknowledged benefits in supporting and maintaining overall health and wellness.
Expensive, state-of-the-art medical devices and surgeries often are thwarted by the body's natural response to attack something in the tissue that appears foreign. Now, University of Washington engineers have demonstrated in mice a way to prevent this sort of response. Their findings were published online this week in the journal Nature Biotechnology.
A commentary and review provides clinicians with the optimal utilization of aspirin to treat and prevent heart attacks, and advice on aspirin in the prevention of colorectal and other cancers.
Nanopharmaceuticals are beginning to demonstrate their capacity to place the drugs directly in the tumor, where they will do the most good, rather than let them roam freely in the body.
A Wayne State University researcher has successfully tested a technique that can lead to more effective use of nanoparticles as a drug delivery system.
New VA, U-M research finds no increased risk of abnormal heart rhythms, death despite FDA warning against high-dose citalopram dosages.
Papers presented in pair of leading neurosurgical journals reveal interesting new findings on dabigatran etexilate (Pradaxa®) and intracranial hemorrhage.
JACKSONVILLE, Fla. — Researchers at Mayo Clinic’s campus in Florida have discovered a protein that is overly active in every human sample of kidney cancer they examined. They also found that an experimental drug designed to block the protein’s activity significantly reduced tumor growth in animals when used alone. Combining it with another drug already used to treat the cancer improved the effectiveness of both.
Selective serotonin reuptake inhibitors (SSRIs) – among the most widely prescribed antidepressant medications – are associated with increased risk of bleeding, transfusion, hospital readmission and death when taken around the time of surgery, according to an analysis led by researchers at UC San Francisco and Baystate Medical Center in Springfield, Mass.
Absorption Pharmaceuticals announced today that the U.S. Patent and Trademark Office has indicated that it will grant a patent related to the use of its topical medication, Promescent, for premature ejaculation (PE). The patent protects novel lidocaine-only eutectic formulation which enables maximum absorption of the anesthetic through the skin's outer layer and provides men with improved ejaculatory control while maintaining great sensory feeling.
ASHP is encouraged by provisions in draft legislation released today by the Senate HELP Committee to address regulatory gaps in the oversight of compounding outsourcers. The draft bill creates a boundary between traditional pharmacy compounding and defines a new entity, “compounding manufacturer.”
Liver fibrosis results from an excessive accumulation of tough, fibrous scar tissue and occurs in most types of chronic liver diseases. In industrialized countries, the main causes of liver injury leading to fibrosis include chronic hepatitis virus infection, excess alcohol consumption and, increasingly, nonalcoholic steatohepatitis (NASH).
Immudex has entered into a strategic agreement with the US Cancer Immunotherapy Consortium (CIC) of the Cancer Research Institute, and the European Association for Cancer Immunotherapy (CIMT), under which Immudex will provide MHC-peptide multimer and Elispot proficiency panel services worldwide.
Researchers have long known that cancerous tumors grow collections of abnormal blood cells, the fuel that feeds this disease and keeps it growing. Now, new evidence in an animal model suggests that blood vessels in the fat tissue of obese individuals could provide the same purpose—and could provide the key to a new way for people to lose weight.
Although the drug zoledronic acid slows bone loss in osteoporosis patients, it also boosts levels of a biomarker that stops bone formation, according to a recent study accepted for publication in The Endocrine Society’s Journal of Clinical Endocrinology & Metabolism (JCEM).
Scientists have overcome a major impediment to the development of effective stem cell therapies by studying mice that lack CD47, a protein found on the surface of both healthy and cancer cells. Researchers at the National Cancer Institute discovered that cells obtained from the lungs of CD47-deficient mice, but not from ordinary mice that have the CD47 gene, multiplied in a culture dish and spontaneously converted into stem cells.
Projected to start in the second half of 2013, researchers at Stony Brook University plan to begin phase IIa placebo-controlled clinical trials using a drug treatment method developed here to treat cellulite. The treatment method is licensed to BioSpecifics Technologies Corp. (“BSTC”), sublicensed to Auxilium Pharmaceuticals, Inc., (“Auxilium”), and uses clostridial collagenase histolyticum (“CCH”), an injectable form of the enzyme collagenase.
A new procedure that thickens and thins fluid at the micron level could save consumers and manufacturers money, particularly for soap products that depend on certain molecules to effectively deal with grease and dirt. Researchers at the University of Washington published their findings online April 9 in the Proceedings of the National Academy of Sciences.
• Ibrutinib disrupts the CLL-driving B-cell receptor signaling pathway. • Phase II trial showed the drug was well tolerated and effective against CLL regardless of del 17p status. • The drug was effective against disease in blood, lymph nodes, spleen and bone marrow.
• Patients received sapacitabine and seliciclib as sequential treatments. • Several patients with BRCA mutations achieved disease response or experienced prolonged stable disease. • BRCA mutation carrier status may be a potential biomarker for response.
• Women with highest expression of drug’s target protein benefited most. • If further confirmed, drug may represent new treatment option in ovarian cancer. • Future study will compare the drug to standard chemotherapy.
Physician-researchers at UT Southwestern have identified a vulnerability of certain lung-cancer cells – a specific genetic weakness that can be exploited for new therapies.
Building upon 30 years of research, Mark Buller, Ph.D., professor of molecular microbiology and immunology at Saint Louis University, studies protecting U.S. armed forces against pox viruses.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right